Abstract
Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 135-152 |
| Number of pages | 18 |
| Journal | Advances in Therapy |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2018 |
Keywords
- Adult T-cell leukemia–lymphoma
- Chemotherapy
- Human T-cell lymphotropic virus type 1
- Oncology
- Relapsed/refractory disease
- Targeted agents
ASJC Scopus subject areas
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies'. Together they form a unique fingerprint.
Cite this
Hermine, O., Ramos, J. C., & Tobinai, K. (2018). A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies. Advances in Therapy, 35(2), 135-152. https://doi.org/10.1007/s12325-018-0658-4